Reem Karmali, MD, MS

Panelists discuss how CAR T therapy is being positioned within the treatment paradigm for marginal zone lymphoma based on emerging efficacy and safety data.

Panelists discuss how emerging evidence supports the use of CAR T therapy for patients with relapsed or refractory marginal zone lymphoma.

Panelists discuss how clinicians identify and address ongoing unmet needs in treating relapsed or refractory marginal zone lymphoma.

Panelists discuss how the treatment landscape for relapsed or refractory marginal zone lymphoma continues to evolve with emerging targeted and immune-based therapies.

Panelists discuss how novel CAR T strategies are being studied to further improve outcomes in follicular lymphoma.

Panelists discuss how clinicians compare safety profiles and manage risks between different CAR T therapies for relapsed or refractory follicular lymphoma.

Panelists discuss how safety profiles differ between CAR T therapy and bispecific antibodies for patients with relapsed or refractory follicular lymphoma.

Panelists discuss how clinicians decide between CAR T therapy and bispecific antibodies for patients with relapsed or refractory follicular lymphoma.

Panelists discuss how determining the best timing for CAR T therapy can maximize outcomes in relapsed or refractory follicular lymphoma.

Panelists discuss how individual and disease-specific factors influence the success of CAR T therapy in relapsed or refractory follicular lymphoma.

Panelists discuss how pivotal trials have established the efficacy and safety of CAR T therapies for relapsed or refractory follicular lymphoma.

Panelists discuss how clinicians determine when and how to use CAR T-cell therapy in relapsed or refractory follicular lymphoma.

Panelists discuss how CAR T-cell therapy and bispecific antibodies are being integrated into care for relapsed or refractory follicular lymphoma.

Panelists discuss how clinicians evaluate the advantages and limitations of therapies used in earlier lines of follicular lymphoma treatment.

Panelists discuss how clinicians approach selecting the most appropriate second-line treatments for relapsed or refractory follicular lymphoma.

Panelists discuss how advances in the understanding of follicular lymphoma have shaped evolving treatment strategies for patients with relapsed or refractory disease.

Reem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.

Reem Karmali, MD, MS, discusses an analysis examining clinical outcomes and predictors of survival in older patients with mantle cell lymphoma in the era of rituximab.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Reem Karmali, MD, MS, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the next steps for research regarding the use of ibrutinib (Imbruvica) as maintenance therapy in mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses challenges in the field of mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the toxicity profile of ibrutinib (Imbruvica) maintenance therapy after induction therapy in patients with mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the use of novel agents in patients with relapsed/refractory mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the preliminary results of a study which examined ibrutinib (Imbruvica) maintenance following induction in treatment-naïve patients with mantle cell lymphoma (MCL).